vs
C4 Therapeutics, Inc.（CCCC）与Maase Inc.（MAAS）财务数据对比。点击上方公司名可切换其他公司
C4 Therapeutics, Inc.的季度营收约是Maase Inc.的1.1倍（$11.0M vs $9.9M）
C4 Therapeutics是一家临床阶段生物制药企业，专注于开发靶向蛋白降解疗法，用于治疗癌症及其他存在重大未满足医疗需求的严重疾病。公司依托自有专利TORPEDO平台设计小分子降解剂清除致病蛋白，目前拥有多条肿瘤领域研发管线，并与头部制药企业达成战略合作。
CCCC vs MAAS — 直观对比
营收规模更大
CCCC
是对方的1.1倍
$9.9M
损益表 — Q4 FY2025 vs Q2 FY2023
| 指标 | | |
|---|---|---|
| 营收 | $11.0M | $9.9M |
| 净利润 | $-20.5M | — |
| 毛利率 | — | 78.7% |
| 营业利润率 | -210.1% | -55.9% |
| 净利率 | -186.0% | — |
| 营收同比 | 112.8% | — |
| 净利润同比 | 40.7% | — |
| 每股收益（稀释后） | $-0.09 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CCCCMAAS
| Q4 25 | $11.0M | — | ||
| Q3 25 | $11.2M | — | ||
| Q2 25 | $6.5M | — | ||
| Q1 25 | $7.2M | — | ||
| Q4 24 | $5.2M | — | ||
| Q3 24 | $15.4M | — | ||
| Q2 24 | $12.0M | — | ||
| Q1 24 | $3.0M | — |
净利润CCCCMAAS
| Q4 25 | $-20.5M | — | ||
| Q3 25 | $-32.2M | — | ||
| Q2 25 | $-26.0M | — | ||
| Q1 25 | $-26.3M | — | ||
| Q4 24 | $-34.6M | — | ||
| Q3 24 | $-24.7M | — | ||
| Q2 24 | $-17.7M | — | ||
| Q1 24 | $-28.4M | — |
营业利润率CCCCMAAS
| Q4 25 | -210.1% | — | ||
| Q3 25 | -306.4% | — | ||
| Q2 25 | -441.0% | — | ||
| Q1 25 | -402.9% | — | ||
| Q4 24 | -728.4% | — | ||
| Q3 24 | -183.9% | — | ||
| Q2 24 | -178.6% | — | ||
| Q1 24 | -1060.2% | — |
净利率CCCCMAAS
| Q4 25 | -186.0% | — | ||
| Q3 25 | -286.4% | — | ||
| Q2 25 | -402.6% | — | ||
| Q1 25 | -363.7% | — | ||
| Q4 24 | -667.8% | — | ||
| Q3 24 | -160.6% | — | ||
| Q2 24 | -147.6% | — | ||
| Q1 24 | -933.2% | — |
每股收益（稀释后）CCCCMAAS
| Q4 25 | $-0.09 | — | ||
| Q3 25 | $-0.44 | — | ||
| Q2 25 | $-0.37 | — | ||
| Q1 25 | $-0.37 | — | ||
| Q4 24 | $-0.50 | — | ||
| Q3 24 | $-0.35 | — | ||
| Q2 24 | $-0.26 | — | ||
| Q1 24 | $-0.41 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $74.6M | $10.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $256.6M | $31.6M |
| 总资产 | $359.1M | $47.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CCCCMAAS
| Q4 25 | $74.6M | — | ||
| Q3 25 | $58.8M | — | ||
| Q2 25 | $78.2M | — | ||
| Q1 25 | $51.3M | — | ||
| Q4 24 | $55.5M | — | ||
| Q3 24 | $59.6M | — | ||
| Q2 24 | $73.1M | — | ||
| Q1 24 | $89.7M | — |
股东权益CCCCMAAS
| Q4 25 | $256.6M | — | ||
| Q3 25 | $154.4M | — | ||
| Q2 25 | $174.1M | — | ||
| Q1 25 | $195.1M | — | ||
| Q4 24 | $216.0M | — | ||
| Q3 24 | $242.7M | — | ||
| Q2 24 | $247.1M | — | ||
| Q1 24 | $258.3M | — |
总资产CCCCMAAS
| Q4 25 | $359.1M | — | ||
| Q3 25 | $265.5M | — | ||
| Q2 25 | $296.5M | — | ||
| Q1 25 | $319.5M | — | ||
| Q4 24 | $349.6M | — | ||
| Q3 24 | $376.1M | — | ||
| Q2 24 | $381.1M | — | ||
| Q1 24 | $398.4M | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-22.1M | $-18.2M |
| 自由现金流经营现金流 - 资本支出 | — | $-18.3M |
| 自由现金流率自由现金流/营收 | — | -184.4% |
| 资本支出强度资本支出/营收 | — | 1.0% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流CCCCMAAS
| Q4 25 | $-22.1M | — | ||
| Q3 25 | $-31.2M | — | ||
| Q2 25 | $-12.1M | — | ||
| Q1 25 | $-33.3M | — | ||
| Q4 24 | $-17.9M | — | ||
| Q3 24 | $-24.1M | — | ||
| Q2 24 | $-5.0M | — | ||
| Q1 24 | $-18.1M | — |
自由现金流CCCCMAAS
| Q4 25 | — | — | ||
| Q3 25 | $-31.6M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $-17.9M | — | ||
| Q3 24 | $-24.1M | — | ||
| Q2 24 | $-5.2M | — | ||
| Q1 24 | — | — |
自由现金流率CCCCMAAS
| Q4 25 | — | — | ||
| Q3 25 | -281.5% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | -346.5% | — | ||
| Q3 24 | -157.2% | — | ||
| Q2 24 | -43.1% | — | ||
| Q1 24 | — | — |
资本支出强度CCCCMAAS
| Q4 25 | — | — | ||
| Q3 25 | 3.7% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.1% | — | ||
| Q3 24 | 0.1% | — | ||
| Q2 24 | 1.6% | — | ||
| Q1 24 | 0.0% | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CCCC
暂无分部数据
MAAS
| Wealth management | $7.8M | 78% |
| Insurance consulting | $1.0M | 10% |
| Other | $975.0K | 10% |
| Asset management | $168.0K | 2% |
